Estamos realizando la búsqueda. Por favor, espere...
1549
37
172
26128
4138
2532
334
Abstract: Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial Selecting the first antipsychotic agent for the acute phase of a first episode of psychosis (FEP) is a critical task that may impact on the long-term outcome. Despite that, there is a lack of research comparing head-to-head different second-generation antipsychotics at this stage. The aim of this study was to compare the effectiveness of aripiprazole and risperidone in the treatment of the acute phase after a FEP. For that purpose, from February 2011 to October 2018, a prospective, randomized, open-label study was undertaken. Two hundred-sixty-six first-episode, drug-naïve patients were randomly assigned to aripiprazole (n = 136), or risperidone (n = 130) and followed-up for 6-weeks. The primary effectiveness measure was all-cause treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted to assess clinical efficacy. The overall dropout rate at 6-week reached 19.5%. Effectiveness measures were similar between both treatment groups as treatment discontinuation rates (?2 = 1.863; p = 0.172) and mean time until all-cause discontinuation (log rank = 1.421; p = 0.233) showed no statistically significant differences. In terms of clinical efficacy, risperidone proved a statistically significant better performance according to BPRS mean change between baseline and 6-week total score (t = 3.187; p = 0.002). Patients under risperidone treatment were significantly more likely to suffer sex-related adverse events. In conclusion, no differences regarding effectiveness were found between aripiprazole and risperidone for the acute-phase treatment of FEP. Despite the importance of efficacy during this phase of treatment, selecting the most effective treatment for the long-term outcome, requires addressing safety and patient ?s preferences
Fuente: European Neuropsychopharmacology Volume 47, June 2021, Pages 74-85
Editorial: Elsevier
Fecha de publicación: 01/06/2021
Nº de páginas: 12
Tipo de publicación: Artículo de Revista
DOI: doi.org/10.1016/j.euroneuro.2021.02.009
ISSN: 0924-977X,1873-7862
Url de la publicación: https://doi.org/10.1016/j.euroneuro.2021.02.009
Leer publicación
MARCOS GOMEZ REVUELTA
JOSE MARIA PELAYO TERAN
JAVIER VAZQUEZ BOURGON
VICTOR ORTIZ GARCIA DE LA FOZ
JACQUELINE MAYORAL VAN SON
MARIA ROSA AYESA ARRIOLA
BENEDICTO CRESPO FACORRO
Volver